Michael M Gottesman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1872623/publications.pdf

Version: 2024-02-01

214	41,003	8732 75	2558 195
papers	citations	h-index	g-index

229	229	229	35032
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multidrug resistance in cancer: role of ATPâ€“dependent transporters. Nature Reviews Cancer, 2002, 2, 48-58.	12.8	4,873
2	Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter. Annual Review of Biochemistry, 1993, 62, 385-427.	5.0	3,448
3	Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 2006, 5, 219-234.	21.5	3,098
4	Mechanisms of Cancer Drug Resistance. Annual Review of Medicine, 2002, 53, 615-627.	5.0	2,284
5	A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science, 2007, 315, 525-528.	6.0	2,230
6	BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER. Annual Review of Pharmacology and Toxicology, 1999, 39, 361-398.	4.2	1,940
7	Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 1986, 47, 381-389.	13.5	1,902
8	Expression of Multidrug Resistance Gene in Human Cancers. Journal of the National Cancer Institute, 1989, 81, 116-124.	3.0	1,214
9	Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018, 18, 452-464.	12.8	1,181
10	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	2.6	956
11	Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacological Reviews, 2012, 64, 706-721.	7.1	737
12	Is the multidrug transporter a flippase?. Trends in Biochemical Sciences, 1992, 17, 18-21.	3.7	700
13	Multiple-Drug Resistance in Human Cancer. New England Journal of Medicine, 1987, 316, 1388-1393.	13.9	675
14	Mechanisms of Multidrug Resistance in Cancer. Methods in Molecular Biology, 2010, 596, 47-76.	0.4	555
15	Predicting drug sensitivity and resistance. Cancer Cell, 2004, 6, 129-137.	7.7	496
16	HIV-1 Protease Inhibitors Are Substrates for the MDR1 Multidrug Transporter. Biochemistry, 1998, 37, 3594-3601.	1.2	482
17	The Clinical Relevance of Cancer Cell Lines. Journal of the National Cancer Institute, 2013, 105, 452-458.	3.0	479
18	The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Letters, 2006, 580, 998-1009.	1.3	472

#	Article	IF	Citations
19	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell and Molecular Genetics, 1985, 11, 117-126.	0.7	446
20	The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology, 2008, 48, 495-535.	4.2	415
21	The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochemical and Biophysical Research Communications, 1986, 141, 956-962.	1.0	389
22	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18708-18713.	3.3	381
23	Overview: ABC transporters and human disease. Journal of Bioenergetics and Biomembranes, 2001, 33, 453-458.	1.0	304
24	A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 860-871.	1.1	281
25	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes. Cancer Research, 2014, 74, 3913-3922.	0.4	277
26	Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resistance Updates, 2012, 15, 98-105.	6.5	269
27	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. Annual Review of Pharmacology and Toxicology, 2016, 56, 85-102.	4.2	261
28	Human P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State. Biochemistry, 1998, 37, 5010-5019.	1.2	245
29	Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. Journal of the National Cancer Institute, 2010, 102, 1637-1652.	3.0	241
30	Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7449-7454.	3.3	233
31	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	2.0	230
32	Is resistance useless? Multidrug resistance and collateral sensitivity. Trends in Pharmacological Sciences, 2009, 30, 546-556.	4.0	223
33	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Research, 2007, 67, 9609-9612.	0.4	219
34	Drug resistance: Still a daunting challenge to the successful treatment of AML. Drug Resistance Updates, 2012, 15, 62-69.	6.5	218
35	ATPâ€binding properties of P glycoprotein from multidrugâ€resistant KB cells. FASEB Journal, 1987, 1, 51-54.	0.2	209
36	CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered Î²-tubulin. Cell, 1980, 20, 29-36.	13.5	207

#	Article	IF	Citations
37	P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochemical and Biophysical Research Communications, 1989, 162, 224-231.	1.0	179
38	Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance. Chemical Reviews, 2014, 114, 5753-5774.	23.0	172
39	Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9903-9907.	3.3	168
40	Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. Cancer Research, 2006, 66, 4808-4815.	0.4	162
41	Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian Cells. Journal of Biological Chemistry, 1996, 271, 1708-1716.	1.6	160
42	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. Molecular Pharmacology, 2002, 62, 1-6.	1.0	154
43	The â€œSpecificâ€•P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). ACS Chemical Neuroscience, 2011, 2, 82-89.	1.7	153
44	Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity. Journal of Biological Chemistry, 2017, 292, 446-461.	1.6	152
45	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Molecular Cancer Therapeutics, 2008, 7, 3081-3091.	1.9	151
46	Synthesis, Activity, and Pharmacophore Development for Isatin-Î²-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells. Journal of Medicinal Chemistry, 2009, 52, 3191-3204.	2.9	146
47	Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein. Journal of Biological Chemistry, 1996, 271, 1877-1883.	1.6	143
48	Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy. Blood, 1999, 94, 52-61.	0.6	142
49	Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell and Melanoma Research, 2009, 22, 740-749.	1.5	142
50	Measurement of Multidrug-Resistance Messenger RNA in Urogenital Cancers; Elevated Expression in Renal Cell Carcinoma is Associated with Intrinsic Drug Resistance. Journal of Urology, 1988, 139, 862-865.	0.2	140
51	Both ATP Sites of Human P-Glycoprotein Are Essential but Not Symmetric. Biochemistry, 1999, 38, 13887-13899.	1.2	137
52	DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nature Genetics, 1997, 17, 483-486.	9.4	132
53	Genetic basis of multidrug resistance of tumor cells. Journal of Bioenergetics and Biomembranes, 1990, 22, 593-618.	1.0	129
54	Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry, 1990, 29, 2295-2303.	1.2	129

#	Article	IF	Citations
55	Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Research, 1990, 14, 11-21.	0.4	118
56	The Inhibitor Ko143 Is Not Specific for ABCG2. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 384-393.	1.3	113
57	The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. Journal of the National Cancer Institute, 2015, 107, djv222.	3.0	110
58	MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer Research, 2014, 74, 598-608.	0.4	103
59	SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism. Molecular Cancer Research, 2008, 6, 1499-1506.	1.5	101
60	Synthesis and Structureâ€“Activity Evaluation of Isatin-Î²-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein. Journal of Medicinal Chemistry, 2011, 54, 5878-5889.	2.9	101
61	Structural Flexibility of the Linker Region of Human P-Glycoprotein Permits ATP Hydrolysis and Drug Transport. Biochemistry, 1998, 37, 13660-13673.	1.2	99
62	The dynamics of drug resistance: A mathematical perspective. Drug Resistance Updates, 2012, 15, 90-97.	6.5	94
63	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. Journal of Cellular Physiology, 2000, 183, 108-116.	2.0	91
64	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 2007, 8, 29-39.	0.6	91
65	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistanceâ€“linked ABCG2 transporter. Molecular Cancer Therapeutics, 2007, 6, 3287-3296.	1.9	89
66	Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family. Cancer Research, 2012, 72, 5945-5955.	0.4	89
67	Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB Journal, 1994, 8, 766-770.	0.2	87
68	Effect of ABC transporters on HIVâ€1 infection: inhibition of virus production by theMDR1transporter. FASEB Journal, 2000, 14, 516-522.	0.2	87
69	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends in Pharmacological Sciences, 2005, 26, 385-387.	4.0	86
70	Principal expression of two mRNA isoforms (ABCBâ€Š5Î±andABCBâ€Š5Î²) of the ATP-binding cassette transporter geneABCBâ€Š5 in melanoma cells and melanocytes. Pigment Cell & Melanoma Research, 2005, 18, 102-112.	4.0	82
71	The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. International Journal of Cancer, 1993, 54, 456-461.	2.3	80
72	Contribution to Substrate Specificity and Transport of Nonconserved Residues in Transmembrane Domain 12 of Human P-Glycoproteinâ€. Biochemistry, 1998, 37, 16400-16409.	1.2	80

#	Article	IF	Citations
73	Beyond 3D culture models of cancer. Science Translational Medicine, 2015, 7, 283ps9.	5.8	80
74	Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistance. Molecular Pharmacology, 2004, 66, 1397-1405.	1.0	79
75	Influence of Melanosome Dynamics on Melanoma Drug Sensitivity. Journal of the National Cancer Institute, 2009, 101, 1259-1271.	3.0	79
76	Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein. PLoS ONE, 2012, 7, e40717.	1.1	79
77	Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Research, 2003, 63, 5909-16.	0.4	78
78	Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal Antibody. Journal of the National Cancer Institute, 1991, 83, 1386-1391.	3.0	75
79	Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle. Molecular Pharmacology, 2016, 90, 35-41.	1.0	75
80	Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking. ACS Nano, 2013, 7, 10452-10464.	7.3	71
81	Structure of a multidrug transporter. Nature Biotechnology, 2009, 27, 546-547.	9.4	69
82	Cancer gene therapy: an awkward adolescence. Cancer Gene Therapy, 2003, 10, 501-508.	2.2	62
83	Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer. Current Pharmaceutical Biotechnology, 2011, 12, 686-692.	0.9	62
84	Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes. Molecular Pharmacology, 2004, 66, 1004-1010.	1.0	62
85	A Single Amino Acid Residue Contributes to Distinct Mechanisms of Inhibition of the Human Multidrug Transporter by Stereoisomers of the Dopamine Receptor Antagonist Flupentixol. Biochemistry, 1999, 38, 6630-6639.	1.2	60
86	Multidrug Resistanceâ€“Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research, 2012, 18, 3197-3206.	3.2	60
87	The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance. Cancer Research, 2013, 73, 7168-7175.	0.4	59
88	Efficient Expression of Drug-selectable Genes in Retroviral Vectors Under Control of an Internal Ribosome Entry Site. Nature Biotechnology, 1994, 12, 694-698.	9.4	58
89	P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Research, 2003, 63, 3084-91.	0.4	55
90	Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metabolism and Disposition, 2016, 44, 275-282.	1.7	54

#	Article	IF	Citations
91	Molecular manipulations of the multidrug transporter: a new role for transgenic mice ¹. FASEB Journal, 1991, 5, 2523-2528.	0.2	53
92	Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells. Cancer Research, 2006, 66, 2346-2353.	0.4	53
93	A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance. Assay and Drug Development Technologies, 2009, 7, 233-249.	0.6	53
94	Verapamil enhances the toxicity of conjugates of epidermal growth factor withPseudomonas exotoxin and antitransferrin receptor withpseudomonas exotoxin. Journal of Cellular Physiology, 1984, 120, 271-279.	2.0	52
95	Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. Journal of Cellular Physiology, 2005, 202, 635-641.	2.0	52
96	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2593-2598.	3.3	50
97	Model systems for studying the blood-brain barrier: Applications and challenges. Biomaterials, 2019, 214, 119217.	5.7	50
98	Genetic evidence that a phorbol ester tumor promoter stimulates ornithine decarboxylase activity by a pathway that is independent of cyclic AMP-dependent protein kinases in CHO cells. Journal of Cellular Physiology, 1982, 113, 433-439.	2.0	48
99	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.4	48
100	Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells:â€‰ Impact on Drug Disposition and Discovery. Molecular Pharmaceutics, 2006, 3, 87-93.	2.3	45
101	High Cloning Capacity of In Vitro Packaged SV40 Vectors with No SV40 Virus Sequences. Human Gene Therapy, 2003, 14, 167-177.	1.4	43
102	New Potent Verapamil Derivatives that Reverse Multidrug Resistance in Human Renal Carcinoma Cells and in Transgenic Mice Expressing the Human MDR 1 Gene. Journal of Urology, 1991, 146, 447-453.	0.2	41
103	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics, 2009, 8, 2057-2066.	1.9	41
104	N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier. Drug Metabolism and Disposition, 2010, 38, 917-922.	1.7	40
105	Bioluminescent imaging of drug efflux at the bloodâ€“brain barrier mediated by the transporter ABCG2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20801-20806.	3.3	40
106	The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors. Bulletin of Mathematical Biology, 2014, 76, 627-653.	0.9	40
107	Heterogeneity in refractory acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10494-10503.	3.3	40
108	Defeating drug resistance in cancer. Discovery Medicine, 2006, 6, 18-23.	0.5	40

#	Article	IF	Citations
109	Retroviral transfer of a chimeric multidrug resistanceâ€adenosine deaminase gene. FASEB Journal, 1990, 4, 1501-1507.	0.2	39
110	Drug selection with paclitaxel restores expression of linked IL-2 receptor Â-chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3123-3128.	3.3	39
111	Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity. Cancer, 2013, 119, 3076-3083.	2.0	39
112	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. Cancer Letters, 2019, 457, 110-118.	3.2	39
113	In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer. Human Gene Therapy, 2002, 13, 299-310.	1.4	38
114	Transfer of genes to chinese hamster ovary cells by DNA-mediated transformation. Somatic Cell Genetics, 1982, 8, 23-39.	2.7	37
115	Characterization by somatic cell genetics of a monoclonal antibody to theMDR1 gene product (P-glycoprotein): Determination of p-glycoprotein expression in multi-drug-resistant kb and cem cell variants. International Journal of Cancer, 1991, 47, 533-543.	2.3	37
116	Inhibition of Glutathione Peroxidase Mediates the Collateral Sensitivity of Multidrug-resistant Cells to Tiopronin. Journal of Biological Chemistry, 2014, 289, 21473-21489.	1.6	37
117	The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity. Molecular Cancer Therapeutics, 2015, 14, 90-100.	1.9	36
118	Gene Transfer of Drug Resistance Genes Implications for Cancer Therapy. Annals of the New York Academy of Sciences, 1994, 716, 126-143.	1.8	35
119	Studies of Human MDR1-MDR2 Chimeras Demonstrate the Functional Exchangeability of a Major Transmembrane Segment of the Multidrug Transporter and Phosphatidylcholine Flippase. Molecular and Cellular Biology, 1999, 19, 1450-1459.	1.1	35
120	Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin. Journal of Medicinal Chemistry, 2011, 54, 4987-4997.	2.9	35
121	Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Drug Resistance Updates, 2012, 15, 2-4.	6.5	35
122	Regulation and Expression of the ATP-Binding Cassette Transporter ABCG2 in Human Embryonic Stem Cells. Stem Cells, 2012, 30, 2175-2187.	1.4	35
123	Pseudomonas Exotoxin Conjugated to Monoclonal Antibody MRK16 Specifically Kills Multidrug Resistant Cells in Cultured Renal Carcinomas and In Mdr-Transgenic Mice. Journal of Urology, 1993, 149, 174-178.	0.2	34
124	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. FEBS Letters, 1992, 304, 256-260.	1.3	33
125	Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. Journal of Cellular Physiology, 2010, 225, 822-828.	2.0	33
126	Pluripotent Stem Cell Platforms for Drug Discovery. Trends in Molecular Medicine, 2018, 24, 805-820.	3.5	33

#	Article	IF	Citations
127	The Extracellular Loop between TM5 and TM6 of P-Glycoprotein Is Required for Reactivity with Monoclonal Antibody UIC2. Archives of Biochemistry and Biophysics, 1999, 367, 74-80.	1.4	31
128	Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. Molecular Pharmaceutics, 2011, 8, 2080-2088.	2.3	31
129	The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. Methods in Molecular Biology, 2009, 542, 5-54.	0.4	31
130	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. Journal of Cellular Physiology, 1992, 152, 87-94.	2.0	30
131	Multidrug resistant transgenic mice as a novel pharmacologic tool. BioEssays, 1991, 13, 381-387.	1.2	29
132	Identification of Cytoskeletal [¹⁴C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. Molecular Pharmacology, 2004, 66, 789-793.	1.0	29
133	Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance. Molecular Pharmacology, 2006, 69, 1383-1388.	1.0	29
134	P-Glycoprotein is not present in mitochondrial membranes. Experimental Cell Research, 2007, 313, 3100-3105.	1.2	29
135	Modeling intrinsic heterogeneity and growth of cancer cells. Journal of Theoretical Biology, 2015, 367, 262-277.	0.8	29
136	Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response. Cancer Research, 2016, 76, 2882-2890.	0.4	28
137	Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29609-29617.	3.3	28
138	RAB8 Enhances TMEM205-Mediated Cisplatin Resistance. Pharmaceutical Research, 2012, 29, 643-650.	1.7	27
139	Detection of Multidrug Resistance (MDR1) Gene RNA Expression in Human Tumors by a Sensitive Ribonuclease Protection Assay. Japanese Journal of Cancer Research, 1989, 80, 1127-1132.	1.7	26
140	A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry, 2004, 98, 1599-1606.	1.5	26
141	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. Experimental Cell Research, 2020, 388, 111860.	1.2	26
142	Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research, 2004, 293, 283-291.	1.2	25
143	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000Research, 2020, 9, 17.	0.8	25
144	Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials, 2013, 34, 8301-8313.	5.7	23

#	Article	IF	Citations
145	The Role of Abcb5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans. PLoS Medicine, 2015, 12, e1001782.	3.9	23
146	Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Experimental Cell Research, 2013, 319, 566-574.	1.2	22
147	Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Experimental Cell Research, 2015, 336, 318-328.	1.2	22
148	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology, 2019, 96, 629-640.	1.0	22
149	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
150	Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein. Scientific Reports, 2018, 8, 12716.	1.6	21
151	An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2062-2075.	2.4	20
152	Sodium butyrate affects expression of fibronectin on CHO cells: Specific increase in antibody-complement-mediated cytotoxicity. Journal of Cellular Physiology, 1980, 104, 163-170.	2.0	18
153	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Journal of Cellular Physiology, 1993, 155, 414-425.	2.0	18
154	Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells. PLoS ONE, 2011, 6, e17981.	1.1	18
155	P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway. Biochemical Pharmacology, 2013, 86, 584-596.	2.0	18
156	Spatial control of oxygen delivery to threeâ€dimensional cultures alters cancer cell growth and gene expression. Journal of Cellular Physiology, 2019, 234, 20608-20622.	2.0	17
157	Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. Drug Metabolism and Disposition, 2019, 47, 715-723.	1.7	17
158	Efficient Long-Term Coexpression of a Hammerhead Ribozyme Targeted to the U5 Region of HIV-1 LTR by Linkage to the Multidrug-Resistance Gene. Oligonucleotides, 1997, 7, 511-522.	4.4	15
159	The Molecular Mysteries Underlying P-glycoprotein-Mediated Multidrug Resistance. Cancer Biology and Therapy, 2004, 3, 382-384.	1.5	15
160	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. Experimental Cell Research, 2019, 375, 106-112.	1.2	15
161	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter. Scientific Reports, 2021, 11, 24150.	1.6	15
162	Down-Regulation and Altered Localization of Î³-Catenin in Cisplatin-Resistant Adenocarcinoma Cells. Molecular Pharmacology, 2004, 65, 1217-1224.	1.0	14

#	Article	IF	Citations
163	Simplifying the complexity of resistance heterogeneity in metastasis. Trends in Molecular Medicine, 2014, 20, 129-136.	3.5	14
164	Drug Resistance Is Conferred on the Model Yeast Saccharomyces cerevisiae by Expression of Full-Length Melanoma-Associated Human ATP-Binding Cassette Transporter ABCB5. Molecular Pharmaceutics, 2014, 11, 3452-3462.	2.3	14
165	Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. Journal of Biological Inorganic Chemistry, 2015, 20, 1081-1095.	1.1	14
166	Humanâ€“Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1). Biochemistry, 2016, 55, 1010-1023.	1.2	14
167	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3794.	1.8	14
168	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget, 2016, 7, 69804-69815.	0.8	14
169	An epidermal growth factor-ricin a chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. Journal of Cellular Physiology, 1989, 139, 51-57.	2.0	12
170	[42] Retroviral transfer of human MDR1 gene into human T lymphocytes. Methods in Enzymology, 1998, 292, 557-572.	0.4	12
171	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
172	[9] Drug-resistant mutants: Selection and dominance analysis. Methods in Enzymology, 1987, 151, 113-121.	0.4	11
173	In situLocalization of the Human Multidrug-resistance Gene mRNA Using Thymine-Thymine Dimerized Single-stranded cDNA. Japanese Journal of Cancer Research, 1990, 81, 949-955.	1.7	11
174	The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylationâ€“mediated 14-3-3 binding. Journal of Biological Chemistry, 2018, 293, 16142-16159.	1.6	11
175	Rous sarcoma virus transformed cells are resistant to cyclic AMP. Journal of Cellular Physiology, 1982, 111, 42-48.	2.0	10
176	Mutant KB cells with decreased EGF receptor expression: Biochemical characterization. Journal of Cellular Physiology, 1987, 133, 127-134.	2.0	10
177	Genetic characterization of human KB cell lines resistant to epidermal growth factor:Pseudomonas exotoxin conjugates. Journal of Cellular Physiology, 1988, 135, 527-532.	2.0	10
178	Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. Journal of Inorganic Biochemistry, 2015, 149, 45-48.	1.5	10
179	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. Journal of Cellular Physiology, 1988, 135, 502-508.	2.0	8
180	Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. Cancer Chemotherapy and Pharmacology, 2008, 62, 977-984.	1.1	8

#	Article	IF	Citations
181	Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier. Scientific Reports, 2016, 6, 20418.	1.6	8
182	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. Translational Oncology, 2021, 14, 100917.	1.7	8
183	The Evolving AML Genomic Landscape: Therapeutic Implications. Current Cancer Drug Targets, 2020, 20, 532-544.	0.8	8
184	Putative â€œMDR enhancerâ€•is located on human chromosome 20 and not linked to theMDRI gene on chromosome 7. Genes Chromosomes and Cancer, 1994, 10, 267-274.	1.5	7
185	In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Bloodâ€“Brain Barrier. Methods in Molecular Biology, 2016, 1461, 227-239.	0.4	7
186	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. Journal of Investigative Dermatology, 2019, 139, 1985-1992.e10.	0.3	6
187	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. Drug Metabolism and Disposition, 2016, 44, 180-188.	1.7	5
188	Host gene expression modulated by Zika virus infection of human-293 cells. Virology, 2021, 552, 32-42.	1.1	5
189	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS ONE, 2015, 10, e0136396.	1.1	5
190	DNA-mediated transfer of cAMP resistance in CHO cells. Journal of Cellular Physiology, 1986, 127, 89-94.	2.0	4
191	Commentary: A Delicate Balance: Weighing the Effects of Conflict-of-Interest Rules on Intramural Research at the National Institutes of Health. Academic Medicine, 2010, 85, 1660-1662.	0.8	4
192	The Drug Excipient Cyclodextrin Interacts With<scp>d</scp>-Luciferin and Interferes With Bioluminescence Imaging. Molecular Imaging, 2016, 15, 153601211562522.	0.7	4
193	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. Journal of Medicinal Chemistry, 2020, 63, 1434-1439.	2.9	4
194	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
195	Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. , 2009, , 83-88.		4
196	[34] pHaMDR-DHFR bicistronic expression system for mutational analysis of P-glycoprotein. Methods in Enzymology, 1998, 292, 474-480.	0.4	3
197	Codominance of cisplatin resistance in somatic cell hybrids. Journal of Cellular Physiology, 2003, 196, 63-69.	2.0	3
198	Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	3

#	Article	IF	Citations
199	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence. , 2016, , 105-134.		3
200	ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model. , 2021, 4, 620-633.		3
201	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. , 2000, 183, 108.		2
202	How Melanoma Cells Evade Chemotherapy. , 2006, , 591-603.		1
203	Prospects for Gene Therapy of HIV Infections and AIDS. , 0, , 291-318.		0
204	Multidrug Resistance I: P-Glycoprotein. , 2002, , 247-254.		0
205	Identification of gene signatures involved in the mechanisms of multidrug resistance. Personalized Medicine, 2009, 6, 133-134.	0.8	0
206	Rules to Prevent Conflict of Interest for Clinical Investigators Conducting Human Subjects Research. , 2012, , 139-146.		0
207	Gil Ashwell, 1916â€“2014. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16232-16233.	3.3	0
208	Selectable Markers for Gene Therapy. , 2015, , 701-740.		0
209	Inside Cover Image, Volume 234, Number 11, November 2019. Journal of Cellular Physiology, 2019, 234, ii.	2.0	0
210	Understanding the impact of controlled oxygen delivery to 3D cancer cell culture. , 2020, , 661-696.		0
211	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents. , 0, , 429-453.		0
212	Gene Expression and Detection. , 2003, , 413-480.		0
213	Individualized Multidrug Resistance In Acute Myeloid Leukemia. Blood, 2010, 116, 2491-2491.	0.6	0
214	Exploring the complexity of multidrug resistance in cancer (91.1). FASEB Journal, 2014, 28, 91.1.	0.2	0